In addition, adenosine A2a receptor (ADORA2A) antagonists synergize with a variety of immunotherapeutic strategies in a variety of preclinical tumor models, including CAR T-cell therapies in a leukemia model and PD-1 blockers in breast cancer and melanoma models (97). This evidence concerns the gene PDCD1 and neoplasm.